Silo Pharma has received a Notice of Allowance from the United States Patent and Trademark Office for an application covering SPC-15, its lead asset and a novel intranasal therapeutic targeting post-traumatic stress disorder (PTSD). The application covers composition and method claims related to preventing or delaying stress-induced fear, depressive-like and anxiety-like behavioral responses. The invention, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior," also has a corresponding patent issued by the Japan Patent Office earlier this year. A Notice of Allowance means the application has completed examination and been found to meet patentability requirements, although the final U.S. patent has not yet been issued.